Scientists at Lineage Cell Therapeutics hope to treat spinal cord injuries with an allogeneic therapy created from oligodendrocyte progenitor cells.
“We manufacture oligodendrocyte progenitor cells and inject them in the area of the injury,” explains CEO Brian Culley. “The cells occupy the cavity—the hole where healthy cells have died off—and then make myelin and secrete neurotrophic factors to aid recovery.”
In a Phase I/IIa trial of 25 patients, this treatment, known as OPC1, caused no serious adverse events and one-third of the patients experienced substantial motor-skill improvements.
Click here to read full article https://www.genengnews.com/topics/bioprocessing/new-promise-for-spinal-cord-injuries/